

Galectin 3 (LGALS3)

Table of Content

[Purpose](#)
[Description & Definitions](#)
[Criteria](#)
[Coding](#)
[Document History](#)
[References](#)
[Special Notes](#)
[Keywords](#)

[Effective Date](#) 12/2012
[Next Review Date](#) 6/15/2024
[Coverage Policy](#) Medical 304
[Version](#) 3

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details*.

Purpose:

This policy addresses the medical necessity of Galectin 3 (LGALS3).

Description & Definitions:

Galectin 3 (LGALS3) is a protein that is involved with cell growth, cell death, cell division cycle, cell adhesions and other cell functions. Mutations are associated with heart disease, stroke, cancer, fibrosis and inflammation.

Criteria:

Galectin 3 (LGALS3) is considered **not medically necessary** for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
82777	Galectin-3

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2020: January
- 2016: January, April

- 2015: January, February, October
- 2014: July, December
- 2013: January, February, March, July, August, September

Reviewed Dates:

- 2023: June
- 2022: June
- 2021: August
- 2020: August
- 2019: May
- 2018: May
- 2016: June, July

Effective Date:

- December 2012

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Galectin-3 In Vitro Diagnostic Assay. US Food and Drug Administration. (6.12.2023). Retrieved 6.13.2023. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpd/classification.cfm?ID=659>

(2023). Galectin-3 In Vitro Diagnostic Assay (BG Medicine Inc.) For The Management Of Patients With Chronic Heart Failure. Hayes, a symplar company. ARCHIVED (11.24.2016). Retrieved 6.13.2023. <https://evidence.hayesinc.com/report/htb.galectin2719>

(2023). MCG, Informed Care Strategies. (2023). Retrieved 6.13.2023. <https://careweb.careguidelines.com/ed26/index.html>

(2023). Centers for Medicare and Medicaid Services. CMS.gov. Retrieved 6.13.2023. <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=&areald=all&docType=6,3,5,1,F,P&hcpcsOption=code&hcpcsStartCode=82777&hcpcsEndCode=82777&sortBy=title>

(2023). Procedure Fee Files & CPT Codes. Virginia's Medicaid Program. Department of Medical Assistance Services. An Agency of the Commonwealth of Virginia. Retrieved 6.13.2023. <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

(2023). Avalon Optima Health Laboratory Testing Policies. (2023). Retrieved 6.13.2023. <https://www.avalonhcs.com/policies-optimahealth/>

(2023). Aguilar, D., Sun, C., Hoogeveen, R., Nambi, V., Selvin, E., Matsushita, K., Saeed, A., McEvoy, J., Shah, A., Solomon, S., Bowewinkle, E., Ballantyne, CI, American Heart Association. Levels and Change in Galectin-3 and Association with Cardiovascular Events: The ARIC Study. (6.23.2020). Retrieved 6.13.2023. <https://www.ahajournals.org/doi/10.1161/JAHA.119.015405>

(2023). Thomas, L., & Pasquini, L. A. (2018). Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination. *Frontiers in Cellular Neuroscience*. (9.12.2018). PubMed. National Library of Medicine. Retrieved 6.13.2023. <https://pubmed.ncbi.nlm.nih.gov/30258354/>

Boutin, L., Legrand, M., Sadoune, M., Mebazaa, A., Gayat, E., Chadjichristos, C., & Depret, F. (2022, Jan 06). Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission. Retrieved Jun 06, 2022, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/34991653/>

Natriuretic Peptide and Biomarkers Testing for Heart Failure. (2020, May 01). Retrieved Jun 06, 2022, from DynaMed: https://www.dynamedex.com/evaluation/natriuretic-peptide-and-biomarkers-testing-for-heart-failure#GALECTIN_3
Procedure Fee Files & CPT Codes. (2022). Retrieved Jun 06, 2022, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

Nakajima, K., Balan, V., & Raz, A. (2020, Sep 14). Galectin-3: an immune checkpoint target for musculoskeletal tumor patients. Retrieved Aug 02, 2021, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/32929561/>

Ram, T., Lekshmi, A., Somanathan, T., & Sujathan, K. (2021). Galectin-3: A factotum in carcinogenesis bestowing an archery for prevention. Retrieved Aug 02, 2021, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/33998569/>

Special Notes: *

This medical policy expresses Sentara Health Plan's determination of medical necessity of services, and they are based upon a review of currently available clinical information. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Keywords:

SHP Galectin 3, LGALS3, SHP Medical 304, IgE-Binding Protein, MAC-2, Lectin L-29, L-34 CBP-30, Gal-3, Advanced Glycation End-Product Receptor 3, Lectin, Galactoside-Binding, Soluble, 3, Carbohydrate-Binding Protein 35, CBP 35, Galactose-Specific Lectin 3, Laminin-Binding Protein, 35 KDa Lectin, Galactoside-Binding Protein, GALBP, heart disease, stroke, cancer, fibrosis, inflammation, cell growth, cell death, cell division cycle, cell adhesions, L31; GAL3; MAC2; GALIG; LGALS2